Press Releases

Chronic Exposure to Low Levels of Blast May Be Associated with Neurotrauma

Scientists at the Walter Reed Army Institute for Research demonstrated that biomarkers associated with traumatic brain injury were elevated among law enforcement and military personnel, particularly in active duty participants with longer duration of service. Most notably, these elevated biomarker levels were observed in individuals without a diagnosed brain injury or concussion.

Accelerated Cellular Aging Associated with Mortality Seen in Depressed Individuals

Cells from healthy individuals with major depressive disorder were found to have higher than expected rates of methylation at specific sites on their DNA, when compared to cells from healthy individuals without MDD, according to a study by a multidisciplinary team. Moving forward, the researchers hope to determine whether pharmacological treatments or therapy may mitigate some methylation changes related to MDD in hopes of normalizing the cellular aging process in affected individuals before it advances.

Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins

A unique vaccine to protect against COVID-19 begins clinical testing Tuesday, 6 April, at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command. Scientists developed a nanoparticle vaccine, based on a ferritin platform, which offers a flexible approach to targeting multiple variants of SARS-COV-2 and potentially other coronaviruses as well.

Newly Identified PTSD Biotypes Enable Improved Screening Tools, Shed Light on Divergent Efficacy of PTSD Treatments

Researchers from the PTSD Systems Biology Consortium, led by scientists from the Walter Reed Army Institute of Research, have identified distinct biotypes for post-traumatic stress disorder, the first of their kind for any psychological disorder. “These biotypes can refine the development of screening tools and may explain the varying efficacy of PTSD treatments”, said Dr. Marti Jett, leader of the consortium and WRAIR chief scientist.

WRAIR Continues Its Fight against Drug-resistant Bacteria and Wound Infections

Though the COVID-19 pandemic remains a top priority for the U.S. Army and government’s healthcare and medical research apparatus, SARS-CoV-2 is just one of many ongoing infectious disease-related public health concerns. Antibiotic-resistant bacteria remain a significant threat to the public as well as Service Members, on and off the battlefield.